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Urgent need for multi-site controlled trials for
CMV pneumonia treatment in African children
The paper by Jeena et al. on cytomegalovirus (CMV)
in South African children with severe pneumonia, and
the accompanying editorial by Gie and Goussard in
the December 2017 issue of this Journal1,2 highlight a
neglected but very important issue:3–6 Despite the
availability of vaccines for Haemophilus influenzae
type B (Hib) and Streptococcus pneumoniae and
appropriate antibiotics, pneumonia remains the most
important infectious cause of death in children
globally.7 Our recent autopsy study from Zambia
showed that while bacterial causes of pneumonia are
important, there is a high burden of undiagnosed
tuberculosis (TB), CMV and other infectious and
non-infectious pathologies, including co-morbidities,
resulting in fatal outcomes.5 World Health Organi-
zation guidelines focus on clinical management and
antibiotic regimens that fail to address the key factors
driving the continued high burden of pneumonia in
children: 1) drug-resistant bacterial pneumonia, 2)
undiagnosed TB or CMV pneumonia, 3) co-infection
with multiple bacterial or viral pathogens or non-
communicable disease (NCD) co-morbidity, and 4)
late referral and overall poor quality care due to lack
of trained staff and equipment.
The first three factors can be addressed through
improvements in diagnostics and services. CMV
diagnosis is complex, and Gie and Goussard rightly
suggest that high fidelity diagnostics could be designed
for CMV, exploiting polymerase chain reaction plat-
forms such as those rolled out for TB or human
immunodeficiency virus (HIV) viral loads to address
this.2 Randomised controlled trials (RCTs) are needed
to assess the impact of empirical treatment for some
common pathogens in high-risk HIV-infected or
-exposed infants, as has proved extremely successful
with respect to cotrimoxazol prophylaxis and Pneu-
mocystis jiroveci pneumonia. Could empirical treat-
ment of CMV and TB, both ubiquitous highly
immunomodulatory and immunologically dominant
pathogens, and proven causes of paediatric pneumonia
deaths,3,5 deliver broader benefits for African children?
The primary CMV drug, ganciclovir (GCV), causes
neutropaenia, and its efficacy in treating CMV
pneumonia in seriously ill African children has not
been evaluated in RCTs. GCV is unavailable outside
South Africa and is not the standard of care across sub-
Saharan Africa due to its high cost, and the lack of
clinical case definitions for using the drug and
indications as to when to stop treatment. Jeena et
al.’s study adds to the growing body of evidence3–6 that
presents a compelling case for conducting RCTs of
GCV in African children to determine the efficacy, dose
and treatment duration of GCV or its oral equivalent,
valganciclovir, which is easily administered and hence
lends itself to study. South African researchers with
experience administering GCV to young infants should
look to collaborate regionally to implement such trials,
and funding bodies should recognise 1) that pneumonia
is the most important infectious cause of death in
children, and 2) that there are multiple causes that need
novel diagnostics and therapeutic strategies.
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